Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...
An article published in the Journal of the European Academy of Dermatology and Venereology investigated the long-term effectiveness and safety of adalimumab in combination with methotrexate versus ...
In people with psoriasis taking adalimumab, there was no significant difference between adalimumab monotherapy and adalimumab with concomitant methotrexate, according to a recent report in JAMA ...
Background. Psoriasis is a chronic, potentially debilitating inflammatory skin disorder associated with erosive arthritis and an increased risk for cardiovascular disease. [1] Management strategies ...
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...
Abbott Park, IL - Abbott Laboratories is seeking US and European regulatory approval to market its TNF inhibitor adalimumab (Humira) for the treatment of psoriatic arthritis (PsA) and as a first-line ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results